Using Value-Agnostic Incentives to Promote Pharmaceutical Innovation.
›
Linked as:Extract
Using Value-Agnostic Incentives to Promote Pharmaceutical Innovation.
No longer available (Autolink)
See the full content of this document
This document cites
- Federal Cases - 570 U.S. 136 (2013), 12-416, Federal Trade Commission v. Actavis, Inc.
- Federal Cases - 570 U.S. 472 (2013), 12-142, Mutual Pharmaceutical Co., Inc. v. Bartlett
